(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 18.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.84%.
Adma Biologics's revenue in 2025 is $474,174,000.On average, 1 Wall Street analysts forecast ADMA's revenue for 2025 to be $120,914,185,317, with the lowest ADMA revenue forecast at $120,914,185,317, and the highest ADMA revenue forecast at $120,914,185,317. On average, 1 Wall Street analysts forecast ADMA's revenue for 2026 to be $153,081,606,239, with the lowest ADMA revenue forecast at $153,081,606,239, and the highest ADMA revenue forecast at $153,081,606,239.
In 2027, ADMA is forecast to generate $189,592,106,246 in revenue, with the lowest revenue forecast at $189,592,106,246 and the highest revenue forecast at $189,592,106,246.